Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
24 sept. 2024 08h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within core activities in RNA delivery, supported by move into new...
Global Exosome Market Size, Forecast, Trials and Trends 2024: Exosome-Based Diagnostics and Therapeutics are Expanding, with 388 Clinical Trials Currently Underway
10 sept. 2024 05h39 HE
|
Research and Markets
Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Global Exosome Market: Size, Forecast, Trials, and Trends, 2024" report has been added to ResearchAndMarkets.com's offering. Exosomes are...
SENISCA appoints Tim Edwards as Chair of the Board
10 sept. 2024 02h00 HE
|
Senisca Ltd
Life-science leader with 30 years of experience to guide SENISCA towards becoming a clinical stage novel senotherapeutics company Exeter, UK — 10 September 2024: SENISCA SENISCA, a biotechnology...
RNA Therapeutics Market Size is expected to reach US$ 948 Million by 2031, Report by CoherentMI
09 sept. 2024 11h10 HE
|
CMI
Burlingame, Sept. 09, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, RNA Therapeutics Market is estimated to value at US$ 2.5 Million in the year 2024 and is anticipated to reach...
RIGImmune Announces Multiple Oral Presentations for Intranasal RIG-101 at European Respiratory Society Congress 2024
09 sept. 2024 07h55 HE
|
RIGImmune
Pre-clinical studies for intranasal RIG-101, a first in class RIG-I agonist, demonstrate potent local innate immune stimulation and pan-viral activity against human rhinovirus, influenza and RSV...
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
12 août 2024 09h02 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Treatment with ZbtbB46 mRNA nanoparticles based on Altamira’s SemaPhore™ delivery technology results in significant reduction in...
ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
30 juil. 2024 09h05 HE
|
ADARx Pharmaceuticals
ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
U.S. mRNA Synthesis Raw Materials (Capping Agents, Nucleotides, Plasmid DNA) Market Research 2024-2030: Growing Academic & Industrial Interest in MRNA Technology to Bolster Growth
10 juil. 2024 10h28 HE
|
Research and Markets
Dublin, July 10, 2024 (GLOBE NEWSWIRE) -- The "U.S. mRNA Synthesis Raw Materials Market Size, Share & Trends Analysis Report, Type (Capping Agents, Nucleotides, Plasmid DNA), Application...
mRNA Synthesis and Manufacturing Market, 2035
27 juin 2024 04h51 HE
|
Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "mRNA Synthesis and Manufacturing Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product, Application Area,...
mRNA Therapeutics Market Report 2024-2030: A Projected $31.3 Billion Opportunity Dominated by Moderna, BioNTech, and CureVac
29 mai 2024 06h59 HE
|
Research and Markets
Dublin, May 29, 2024 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market Size, Share & Trends Analysis, 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global mRNA...